Total Funding
56
79
Total FundingPre-Seed raised
Growth Score
-30 pts
Heat Score
0 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
7620
EndoGene.Bio decodes epigenetics in menstrual blood to unlock patient tissue-level insights for therapeutic discovery and diagnostics.
- Maria Teresa Pérez Zaballos: CEO - founder
- Cristina Fernandez Molina: Head of Science - CSO
About the Company
Endogene.bio was founded to solve the lack of molecular data that keeps endometriosis a clinical black box. By analyzing key cells in menstrual blood, the company delivers tissue-level insights with the convenience of a liquid biopsy. Its platform integrates a proprietary database of single-cell epigenetics, transcriptomics with omics ML advanced
algorithms to enable earlier diagnosis, patient stratification, and targeted drug discovery. With proprietary datasets, clinical validation, and pharma interest, endogene.bio is unlocking molecular medicine in a €180B+ women’s health market.
Hispanic / Latine Founded
Women Founded
Women Led
